Article info
PDFSystemic lupus erythematosus
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
- Correspondence to Professor Murray B Urowitz , Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto Senior Scientist, Krembil Research Institute, Toronto Western Hospital, Toronto, ON M5T 2S8, Canada ; m.urowitz{at}utoronto.ca
Citation
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
Publication history
- Received July 3, 2018
- Revised November 1, 2018
- Accepted November 12, 2018
- First published January 4, 2019.
Online issue publication
July 12, 2020
Article Versions
- Previous version (2 August 2019).
- You are viewing the most recent version of this article.
Copyright information
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/